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Myeloid cell–mediated destruction of myelin 
sheets and axons is thought to be the primary 
mechanism leading to loss of motor function 
in multiple sclerosis and experimental autoim-
mune encephalomyelitis (EAE; Benveniste, 1997). 
The myeloid effector populations in the central 
nervous system (CNS) consist of resident acti-
vated microglia and blood-derived mononu-
clear cells including monocytes, macrophages, 
and DCs. A subpopulation of the infiltrating 
myeloid cells expresses CD11c, MHC class II, 
and CD86 and is often referred to as CNS DCs 
(Deshpande et al., 2007). These effector cells 
have been shown to reactivate antigen-specific   
T cells (Bailey et al., 2007; Deshpande et al., 
2007) and are involved in epitope spreading   
resulting in a remitting-relapsing disease course 
(Miller et al., 2007). In addition to serving as 
antigen-presenting cells, CNS-infiltrating CD11c+ 
inflammatory myeloid cells also display T cell–
independent effector functions through secre-
tion of proinflammatory cytokines and reactive 
oxygen intermediates that can directly contribute 
to progressive demyelination and axon loss 
(Dogan et al., 2008; King et al., 2009).
CMRF-35–like molecule-1 (CLM-1; also 
named MAIR-V, LMIR3, DigR2) is a member 
of the CD300 family of receptors, a multigene 
cluster of type I transmembrane glycoproteins 
with a single extracellular IgV domain on hu-
man chromosome 17 and mouse chromosome   
11 (Márquez et al., 2007; Clark et al., 2009). Two 
receptors in this cluster (CLM-1 and CLM-8) 
contain  an  immunoreceptor  tyrosine-based 
inhibition  motif  (ITIM)  in  their  intracellular 
domains, whereas the remainder of the receptor 
family carries charged residues in the transmem-
brane  region  that  serve  to  recruit  signaling 
adapters.  CLM-1,  the  mouse  orthologue  of 
human CD300f (Clark et al., 2009), was first 
described as a negative regulator of osteoclas-
togenesis in vitro (Chung et al., 2003). Subse-
quent  in  vitro  studies  have  confirmed  that 
CLM-1,  or  its  human  orthologue  CD300f 
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Multiple sclerosis and its preclinical model, experimental autoimmune encephalomyelitis,  
are marked by perivascular inflammation and demyelination. Myeloid cells, derived from 
circulating progenitors, are a prominent component of the inflammatory infiltrate and  
are believed to directly contribute to demyelination and axonal damage. How the cytotoxic 
activity of these myeloid cells is regulated is poorly understood. We identify CMRF-35–like  
molecule-1 (CLM-1) as a negative regulator of autoimmune demyelination. CLM-1 is expressed 
on inflammatory myeloid cells present in demyelinating areas of the spinal cord after immu-
nization of mice with MOG35-55 (myelin oligodendrocyte glycoprotein) peptide. Absence  
of CLM-1 resulted in significantly increased nitric oxide and proinflammatory cytokine 
production, along with increased demyelination and worsened clinical scores, whereas T cell  
responses in the periphery or in the spinal cord remained unaffected. This study thus identi-
fies CLM-1 as a negative regulator of myeloid effector cells in autoimmune demyelination.
© 2010 Xi et al.  This article is distributed under the terms of an Attribution–Non-
commercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.jem.org/misc/terms.shtml). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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absent on irradiation-resistant myeloid cells but present on 
BM-derived donor cells in the inflamed CNS tissue (Fig. 2 A).
Circulating  Ly6ChiCD11b+  inflammatory  monocytes 
have been identified as precursors of CD11c+ DCs present in 
the spinal cord of MOG35-55-immunized mice (Dogan et al., 
2008). GM-CSF–induced recruitment of the inflammatory 
Ly6Chi monocytes from BM immediately before clinical 
manifestation of disease is paralleled by increased disease   
severity in EAE (King et al., 2009), indicating that the Ly6Chi 
monocytes are candidate precursors of CNS-infiltrating cells 
with cytotoxic function. The inflammatory monocyte popu-
lation can be distinguished from resident noninflammatory 
monocytes  based  on  their  expression  levels  of  CX3CR1 
(Geissmann et al., 2003; Auffray et al., 2009b). To determine 
which myeloid cell subset expresses CLM-1, we used CX-
3CR1GFP/+ mice in which one allele for the gene encoding 
CX3CR1 has been replaced with the gene encoding GFP, 
resulting in GFP labeling of all cells from the monocyte/DC/
macrophage lineage including microglia (Geissmann et al., 
2003). In peripheral blood, CLM-1 was expressed on CX3C
R1loLy6ChiCD115+CD62L+Ly6G  inflammatory  mono-
cytes (Geissmann et al., 2003; Auffray et al., 2009a) before 
disease onset but was absent on CX3CR1hi-resident mono-
cytes in both naive and immunized mice (Fig. 2 B and Fig. 
S1 C). This suggests that CLM-1 is associated with inflamma-
tory monocytes that act as precursors of cytotoxic CD11c+ 
cells in the spinal cord. In the CNS, consistent with the expres-
sion of CX3CR1 on infiltrating myeloid cells (Sunnemark   
et al., 2005), CLM-1+CX3CR1lo cells were found adjacent to 
the leptomeningeal vessels of the thoracic spinal cord on day 
14 after immunization, whereas CX3CR1hi ramified microg-
lia cells, which are primarily located in the gray matter of the 
spinal cord, did not express CLM-1 (Fig. 2, C and D). Based 
on these observations, we hypothesized that CLM-1 may 
regulate pathological responses of CNS-infiltrating myeloid 
effector  cells  but  not  of  CNS-resident  microglial  cells  in 
MOG35-55-induced EAE.
Absence of CLM-1 results in increased disease severity  
in MOG35-55–induced EAE
Based on the expression of CLM-1 on inflammatory mono-
cytes and CNS-infiltrating CD11c+ cytotoxic effector cells, 
we next determined if CLM-1 acts to attenuate myeloid 
cell–mediated inflammatory responses in MOG35-55-induced 
EAE. Mice were generated in which exon 1 of CLM-1 was 
deleted through homologous recombination (Supplemental 
material and Fig. S2 A). Successful ablation of the CLM-1 
gene in KO mice was confirmed by PCR (Fig. S2 B), West-
ern blot analysis of BM-derived DCs (BMDCs; Fig. 3 A), 
and flow cytometry (Fig. 3 B) and immunohistochemistry 
(Fig. 3 C) analyses of CD11b+CD11c+ cells isolated from 
inflamed spinal cord. CLM-1 KO mice were viable and born 
in the expected Mendelian ratios. Mice did not differ in 
weight or bone parameters measured at 6 wk of age (unpub-
lished data). Numbers of myeloid and lymphoid cell subsets 
in the inguinal LNs, spleens, and blood were similar in 
(also named IREM-1), serves as an inhibitory receptor in   
myeloid cells (Alvarez-Errico et al., 2004; Fujimoto et al., 
2006; Izawa et al., 2007, 2009). One study finds that CLM-1 
mediates caspase-independent cell death upon cross-linking 
with antibodies (Can et al., 2008). So far, a biological role 
in autoimmune disease has not been described. In this paper, 
we show that CLM-1 is expressed on iNOS- and TNF-
producing inflammatory myeloid cells that invade the spinal 
cord after myelin oligodendrocyte glycoprotein (MOG35-55) 
immunization. We further demonstrate that CLM-1 acts as 
a negative regulator of myeloid cell activity in vivo by sup-
pressing the release of inflammatory cytokines and reactive 
oxygen  species.  This  study  thus  identifies  CLM-1  as  a   
myeloid-specific negative regulator of CNS inflammation 
and demyelination.
RESULTS AND DISCUSSION
CLM-1 is expressed on BM-derived CD11c+ cells at sites  
of CNS inflammation
A genome-wide search was performed to identify single trans-
membrane Ig superfamily members containing an ITIM (Yu 
et al., 2009). Mouse homologues of the candidate ITIM-
containing genes were then selected based on their specific   
expression on myeloid cells and expression levels in the spinal 
cord after immunization with MOG35-55 peptide. Of all candi-
date ITIM genes, CLM-1 messenger RNA (mRNA) levels 
showed the highest fold increase (>1,500-fold) relative to naive 
mice at 2 wk after immunization (Fig. 1 A). Monoclonal anti-
bodies to CLM-1 extracellular domain (ECD) were generated 
to determine the cellular source of CLM-1. CLM-1 was absent 
on the CD11b+ local microglia population in naive mice 
(Fig. 1 B, left). In spinal cords from MOG-immunized mice, 
CLM-1  was  highly  expressed  on  CD11b+CD11c+  myeloid 
cells that also expressed MHC class II, CD86, and Gr-1 (Fig. 1 
B, right; and Fig. S1 B). Immunohistochemical studies further 
illustrated that CLM-1+CD11c+ cells appear in clusters located 
predominantly in the ventrolateral funiculi of the cervical spinal 
cord  (Fig.  1  C).  Although  CNS-resident  CD45loCD11b+CD11c 
microglia cells did not express CLM-1 and iNOS and expressed 
low levels of TNF, CD45hiCD11b+ BM-derived myeloid cells 
present in spinal cord at the onset and peak of disease expressed 
CLM-1, iNOS, and TNF (Fig. 1 D). A subset of CLM-1+ cells 
also expressed CD11c and, therefore, displayed characteristics 
of the TNF- and iNOS-producing (Tip) DCs that were origi-
nally described by Serbina et al. (2003).
We next determined the origin of the CLM-1+ cells present 
in the inflamed spinal cord. Because CNS-resident microglia 
can transform into cells with DC-like characteristics after im-
mune stimulation (Fischer and Reichmann, 2001), we deter-
mined  if  the  CLM-1–positive  cells  in  the  inflamed  CNS 
derive from irradiation-sensitive hematopoietic cells or from 
irradiation-resistant  CNS-resident  microglia.  Mice  bearing 
the allotypic CD45.1 marker were irradiated and reconsti-
tuted with BM cells from donor mice with the CD45.2 
allotype. Consistent with the lack of CLM-1 expression on 
resident microglia in the naive spinal cord, CLM-1 was   JEM VOL. 207, January 18, 2010  
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Figure 1.  CLM-1 is expressed on myeloid cells in CNS inflammatory lesions. (A) CLM-1 mRNA expression in spinal cord after MOG35-55 immuniza-
tion. Fold induction is calculated based on day 0 values. Values are expressed as means ± SEM. (B) CLM-1 expression on CD11b+CD11c+ cells in the spinal 
cord of naive and MOG35-55-immunized mice. (C) Clusters of CLM-1+ CD11c+ myeloid cells in the ventrolateral funiculi and adjacent to leptomeninges 
(dotted line) of the cervical spinal cord (rectangle enlarged in middle and right). Bar, 10 µm. (D) TNF, iNOS, and CLM-1 expression on CD45loCD11b+-resident 
microglia (top row) and on CD45hiCD11b+-infiltrating BM-derived cells. Open histograms represent antigen-specific staining and shaded histograms  
represent isotype control. Results shown are from one experiment out of three, with five (A), three (C), or two (B and D) mice per experimental group.10 CLM-1 is an inhibitor of demyelination | Xi et al.
Figure 2.  CLM-1 expression on irradiation-sensitive myeloid cells infiltrating the CNS and on inflammatory monocytes in the circulation. 
(A) CLM-1 expression on recipient (CD45.1+) or donor (CD45.2+)-derived myeloid cells as determined by immunohistochemistry (left) and flow cytometry 
(right). (B) CLM-1 expression on CX3CR1loCD11b+ inflammatory monocytes and CX3CR1hiCD11b+-resident monocytes 7 d after MOG35-55 immunization.  
(C) CX3CR1 and CLM-1 expression in a thoracic spinal cord section 14 d after immunization. CX3CR1loCLM-1+ cells are localized in the ventromedian  
funiculi (arrowheads) close to the leptomeninges (dotted line). CX3CR1hiCLM-1 cells (arrows) are present throughout the white and gray matter of the 
ventral horn. Enlarged views of the rectangle show nonoverlapping staining of CLM-1 on a cell with a dendritic-like morphology and high CX3CR1-GFP 
expression on a ramified microglia cell. (D) CLM-1 expression on CD45hiCX3CR1lo BM-derived myeloid cells and CD45loCX3CR1hi microglia. Open histo-
grams in A, B, and D represent antigen-specific staining and shaded histograms represent isotype controls. Results shown are from one experiment out  
of two (A and C) or three (B and D), with four (A) or two (B–D) mice per experimental group. Bars: (A and enlarged views in C) 10 µm; (C) 100 µm.JEM VOL. 207, January 18, 2010  11
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Figure 3.  Lack of CLM-1 on BM-recruited cells or treatment with a CLM-1-Fc fusion protein increases EAE disease severity. (A) CLM-1 pro-
tein expression in BMDCs obtained from CLM-1 WT and KO mice. (B) Surface-expression of CLM-1 on CD11c+ myeloid cells isolated from inflamed spinal 
cords of CLM-1 WT and KO mice. Shaded histograms represent isotype control. (C) CLM-1 staining on CD11c+ myeloid cells in inflamed spinal cords from 
WT and KO mice. Bar, 10 µm. (D) Clinical scores in CLM-1 WT and KO mice. (E) Clinical scores in WT mice treated with CLM-1-Fc or control fusion protein. 
(F and G) Clinical scores and mortality in irradiated chimeras consisting of CLM-1 WT or KO mice reconstituted with BM cells from CLM-1 WT or CLM-1 
KO mice. Results shown in A–C are from one of two experiments with two mice per group. Values shown in D–G are means ± SEM from one experiment 
out of three (D and E) or two (F and G) with 14–18 mice per group. *, P < 0.05; **, P < 0.01. AUC, area under curve.
CLM-1 KO and WT mice (unpublished data), indicating 
that CLM-1 absence does not influence the rate of cellular 
turnover. Expression levels of cell surface molecules associ-
ated with antigen presentation and costimulation were simi-
lar on CD11b+CD11c+ cells isolated from CLM-1 WT and 
KO spinal cords at the peak of disease (Fig. S2 C). Expres-
sion levels of other members of the CMRF cluster were 
similar in resting and LPS-stimulated BMDCs derived from 12 CLM-1 is an inhibitor of demyelination | Xi et al.
Increased myeloid cell activation and demyelination in mice 
lacking CLM-1
Next, we determined whether CLM-1 influenced reactiva-
tion of CNS-infiltrating CD4+ T cells. Spinal cord leuko-
cytes harvested from CLM-1 WT and KO mice at the peak 
of disease and restimulated with MOG35-55 showed similar 
polarization toward Th1, Th17, and Foxp3+ T reg cells and 
similar T cell–specific cytokine responses (Fig. 5 A, top row; 
and Fig. S4 G). In contrast, leukocytes harvested from spinal 
cords of CLM-1 KO mice produced significantly elevated 
levels of nitric oxide and myeloid-specific proinflammatory 
cytokines as compared with WT mice (Fig. 5 A, bottom 
row). Thus, CLM-1 negatively regulates local myeloid effec-
tor function in the CNS without affecting T cell responses. 
Because microglia do not express CLM-1 and iNOS, and 
given the relatively small (10%) contribution of microglia 
to the total myeloid cell population harvested from the CNS 
at day 15 after MOG immunization, it seems likely that the 
increased NO2
 and myeloid proinflammatory cytokine pro-
duction is contributed by the infiltrating myeloid cells and 
not by microglia.
Increased  production  of  reactive  nitrogen  species  and   
release of proinflammatory cytokines by myeloid cells has 
been implicated in demyelination in EAE and multiple scle-
rosis (Hooper et al., 1997; Dogan et al., 2008). Therefore, we 
further determined if enhanced cytotoxic activity of myeloid 
cells  in  the  spinal  cord  leads  to  increased  demyelination. 
CLM-1–positive cells were found clustered at sites of demy-
elination in the dorsal and ventral funiculi of the cervical and 
thoracic spinal cord. The cells were found apposed to, and 
often wrapped around, myelin sheets with, in some cases, 
MOG-positive  myelin  remnants  present  inside  CLM-1–
positive cells (Fig. 5 B). Consistent with a role of CLM-1 in 
reducing myeloid effector responses, lack of CLM-1 resulted 
in increased demyelination (Fig. 5, C and D; and Fig. S3, C, 
H, and I), whereas numbers of infiltrating leukocytes remained 
unaltered (Fig. 5 E). Thus, CLM-1 negatively regulates myeloid 
cell activation in the inflamed spinal cord.
Even though the identification of receptors expressed by 
genes in the CMRF/CD300 gene cluster has been completed 
(Clark et al., 2009), their biological role is still poorly under-
stood. For the first time, this study identifies CLM-1 as a 
negative regulator of myeloid effector cells recruited from 
peripheral  blood  to  the  CNS  after  MOG  immunization 
(Dogan et al., 2008; King et al., 2009). The characterization 
of CLM-1 as an inhibitory receptor in vivo is consistent with 
previous in vitro studies (Chung et al., 2003; Alvarez-Errico 
et al., 2004; Izawa et al., 2007) that have demonstrated a role 
for the cytoplasmic ITIM domain of CLM-1 and its human 
orthologue CD300f in recruiting SHP-1 (Src homology-2 
domain-containing protein tyrosine phosphatases-1), in turn 
inhibiting cellular effector responses.
Although cross-linking of the receptor with antibodies 
may reveal some aspects of CLM-1/CD300f signaling (Alvarez-
Errico et al., 2007; Can et al., 2008; Izawa et al., 2009), iden-
tification of a natural ligand will be crucial to understand 
CLM-1 WT and KO mice (Fig. S2, D and E). Disease inci-
dence was comparable in CLM-1 WT and KO mice upon 
MOG35-55  immunization  (Fig.  S3  A).  However,  disease   
severity was significantly increased in mice lacking CLM-1 
(Fig. 3 D). To determine if the protective role of CLM-1 in 
EAE is regulated by the interaction of CLM-1 ECD with a 
putative ligand, mice were treated with a soluble ectodo-
main of CLM-1 (CLM-1-Fc). Similar to the results obtained 
in CLM-1 KO mice, disease incidence was comparable (Fig. 
S3 B) but disease severity was significantly increased in 
CLM-1-Fc–treated  mice  as  compared  with  mice  treated 
with a control fusion protein (Fig. 3 E). These results suggest 
that CLM-1 is a negative regulator of CNS inflammation, 
potentially through interaction of the CLM-1 ECD with a 
putative ligand. BM chimeras were established to determine 
whether the increased disease severity was a result of the   
absence of CLM-1 on irradiation-sensitive BM-infiltrating 
cells as opposed to irradiation-resistant microglia. CLM-1 
WT mice reconstituted with BM from KO mice showed 
similar disease incidence but increased disease severity com-
pared with WT mice reconstituted with BM from WT mice 
(Fig. 3 F and Fig. S3 D). In contrast, KO mice reconstituted 
with BM from WT mice showed disease severity similar to 
that in WT recipients reconstituted with WT BM (Fig. 3 G 
and Fig. S3 E). Thus, absence of CLM-1 on a population of 
inflammatory BM-derived myeloid cells, but not microglia, 
increases disease severity in EAE.
CLM-1 does not modulate disease-initiating T cell responses
Because  EAE  is  initiated  and  driven  by  antigen-specific 
CD4+ T cells, we further determined if CLM-1 influences 
disease progression through its regulation of effector T cell 
responses in vitro and in vivo. Splenic DCs or BMDCs de-
rived from CLM-1 WT and KO mice were incubated with 
allogeneic CD4+ T cells or with CD4+ T cells expressing a 
TCR specific for OVA peptide. T cell proliferation (Fig. 
S4, A–D) and cytokine responses (Fig. S4 E), as determined 
in this in vitro assay, did not depend on CLM-1 status. To 
further determine if CLM-1 influences T cell priming ex 
vivo, CD4+ T cells isolated from draining LNs (DLNs) 7 d 
after MOG35-55 immunization were isolated and restimu-
lated with MOG35-55 peptide. CLM-1 absence did not sig-
nificantly alter T cell proliferation (Fig. 4 A), generation of 
Foxp3+ regulatory T (T reg) cells (Fig. 4 B and Fig. S4 F), 
or T cell cytokine responses (Fig. 4 C). Finally, to probe a 
potential role for CLM-1 in regulating T cell effector func-
tions in vivo, encephalitogenic CD4+ T cells isolated from 
DLNs of CLM-1 WT and KO donor mice at 10–12 d after 
MOG35-55 immunization were adoptively transferred into 
KO and WT recipients. Disease severity was not influenced 
by CLM-1 status of the T cell donor (Fig. 4 D and Fig. S3 
F) but was significantly enhanced in T cell recipients lacking 
CLM-1 (Fig. 4 E and Fig. S3, G and H). This indicates that 
CLM-1 acts to regulate disease severity at the effector phase, 
but  not  the  T  cell–priming  phase,  of  the  disease  after 
MOG35-55 immunization.JEM VOL. 207, January 18, 2010  13
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be explained by the presence of a 7-aa insertion in the ECD 
of DIgR2 introduced by alternative splicing.
A subset of the CLM-1–expressing myeloid cells in the 
CNS resembles iNOS and TNF-producing myeloid effector 
cells recruited to the spleen after infection with the intracel-
lular pathogen Listeria monocytogenes (Serbina et al., 2003). 
We therefore tested if CLM-1 regulates bactericidal activity 
of myeloid cells toward L. monocytogenes. No significant dif-
ferences were found in live pathogen counts in spleens of 
CLM-1 WT and KO mice at 1, 2, or 6 d after intravenous 
injection of the pathogen (unpublished data), indicating that 
CLM-1 does not influence myeloid cell–driven innate im-
mune responses toward L. monocytogenes.
Together,  our  study  demonstrates  that  CLM-1  plays  a 
nonredundant role in controlling myeloid cell activation and 
CNS demyelination. We further demonstrate that CD11c+ 
inflammatory myeloid cells infiltrating the CNS can affect dis-
ease progression in the absence of altered T cell responses.
CLM-1 biology and may potentially lead to identification of a 
therapeutic for treatment of autoimmune demyelinating dis-
eases. Our results suggest that CLM-1 interacts with a putative 
ligand to modulate myeloid effector function in the CNS. 
Treatment with a soluble version of the receptor increases 
disease  severity  in  EAE,  phenocopying  the  CLM-1  KO 
mouse. One explanation for this is that the recombinant solu-
ble receptor competitively inhibits the binding of a ligand that 
activates CLM-1, thus preventing down-modulation of im-
mune  responses  in  the  immune-privileged  CNS.  Previous 
studies have demonstrated binding of a CLM-1 spliced vari-
ant, DigR2, to a putative ligand on T cells resulting in nega-
tive regulation of T cell responses (Shi et al., 2006). In various 
assays, we have not been able to detect binding of CLM-1 
ECD to T cells, which is compatible with our results showing 
that T cell responses in vitro and in vivo are independent of 
CLM-1 expression on antigen-presenting cells. The different 
findings in our paper compared with the previous paper may 
Figure 4.  CLM-1 absence increases disease severity without affecting T cell priming. (A) T cells isolated from DLNs 7 d after immunization were 
restimulated with MOG35-55 peptide and proliferation was measured by 3H thymidine incorporation. (B) Quantification of Foxp3-expressing CD4+ T cells 
obtained from DLNs of naive CLM-1 WT and KO mice or 14 d after immunization. (C) Cytokine responses of CD4+ T cells obtained from MOG35-55-immunized 
mice restimulated with MOG35-55 peptide ex vivo. (D) Adoptive EAE by transfer of encephalitogenic CD4+ T cells isolated from DLNs of CLM-1 WT or KO 
mice into CLM-1 WT recipients. (E) Adoptive EAE by transfer of encephalitogenic CD4+ T cells isolated from DLNs of CLM-1 WT mice into CLM-1 WT or KO 
recipients. Values are expressed as means ± SEM and experiments have been repeated three times with 6 (A and C), 15–18 (B), 10 (D), and 11 (E) mice per 
group. n.s., not significant. *, P < 0.05; **, P < 0.01. AUC, area under curve.14 CLM-1 is an inhibitor of demyelination | Xi et al.
Figure 5.  Lack of CLM-1 results in increased release of myeloid-specific inflammatory mediators and exacerbated demyelination.  
(A) Production of Th1, Th17, and myeloid cell–specific cytokines by leukocytes isolated from spinal cord 15 d after immunization. (B) CLM-1–positive cells 
apposed to MOG-positive myelin in the dorsal funiculus of the thoracic spinal cord on day 15 after immunization. (C) MOG and CD11c staining in the 
dorsal funiculus of the thoracic spinal cord on day15 after immunization. The lines delineate the area of demyelination. (D) Quantification of demyelin-
ated regions in CLM-1 WT and KO mice. (E) Quantification of infiltrating leukocytes in the spinal cords of WT and KO mice 15 d after MOG immunization. 
Values in E are expressed as means ± SEM of six mice per group. Each symbol represents one individual mouse (A [top row] and D) or a pool of two to 
three mice (A, bottom row). Experiments were repeated twice (A–D) or three times (E) with at least six mice per group. n.s., not significant. *, P < 0.05;  
**, P < 0.01. Bars: (B) 10 µm; (C) 50 µm.JEM VOL. 207, January 18, 2010  15
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Real-time PCR analysis. Total RNA from spinal cords was isolated using 
the RNeasy Protect Mini kit (QIAGEN) and complementary DNA synthe-
sized using the High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). CLM-1 mRNA and 18s ribosomal RNA were measured using 
the TaqMan Universal PCR Master Mix and verified primer and probe sets, 
Mm00467508_m1 and Hs03003631_g1, respectively (Applied Biosystems).
Cytokines.  Cells  isolated  from  spinal  cords  on  day  15  as  previously   
described (Batten et al., 2006) were cultured in RPMI1640 medium with 
and  without  MOG35-55  peptide.  Cytokines  in  culture  supernatants  were 
measured by Luminex (Bio-Plex mouse 23-plex panel; Bio-Rad Laborato-
ries). Nitric oxide production was measured using the Griess assay (Promega) 
according to the manufacturer’s instructions. Ex vivo proliferation and cyto-
kine responses were measured as previously described (Batten et al., 2006).
Immunohistochemistry. Anesthetized mice were transcardially perfused 
with PBS and 4% paraformaldehyde. Spinal cords were immersed in 40% su-
crose and 7-µm thick sections were incubated with the following antibodies: 
anti-CLM-1 and biotin anti-CD45.2 followed by detection with Cy3 anti–
hamster IgG and Alexa Fluor 488–streptavidin (Invitrogen), anti–CLM-1 and 
biotin anti-CD11c (HL3; BD) followed by detection with Cy3 anti–hamster 
IgG and Alexa Fluor 488–Streptavidin, and biotin anti-CD11c and goat anti 
MOG  (R&D)  followed  by  detection  with  Alexa  Fluor  594–streptavidin   
(Invitrogen) and FITC donkey anti–goat antibodies. Sections were cover 
slipped with Prolong Gold anti-fade medium containing DAPI (Invitrogen) 
and examined in a fluorescent microscope (BX-61; Olympus). The area of 
demyelination was quantified using spinal cords stained with the FluoroMy-
elin staining kit (Invitrogen). Images were acquired using a BX-61 micro-
scope at 40× final magnification and analyzed using the MetaMorph software 
package (MDS Analytical Technologies). Intensity thresholds and standard 
morphological filters were applied to identify large contiguous areas of demy-
elination. Results were expressed as total area of demyelination divided by the 
total area of myelination for each spinal cord cross section (Fig. S3 I).
Statistics.  All  p-values  were  calculated  with  an  unpaired  two-tailed   
Student’s t test assuming equal variance.
Online supplemental material. Fig. S1 shows CLM-1 localization on CNS- 
and blood-resident inflammatory myeloid cells. Fig. S2 shows strategy of tar-
geted disruption of the mouse Clm-1 gene and expression analysis. Fig. S3 shows 
EAE incidence and demyelination in CLM-1 WT and KO mice. Fig. S4 shows 
that CLM-1 does not influence T cell responses. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20091508/DC1.
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